[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100653970":3},{"organization":4,"outcomesModule":7,"designInfo":26,"detailedDescription":25,"studyPopulation":25,"armGroups":36,"interventions":50,"overallOfficials":65,"centralContacts":69,"locations":75,"responsibleParty":92,"collaborators":25,"id":96,"slug":97,"hasResults":98,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":25,"eligibilityCriteria":102,"healthyVolunteers":98,"sex":103,"minAge":104,"maxAge":105,"enrollmentInfo":106,"targetDuration":25,"studyType":109,"phases":110,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":78,"whyStopped":25,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":129,"completionDateStruct":131,"leadSponsor":133,"locationsCount":134},{"fullName":5,"class":6},"Sana'a University","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":16,"otherOutcomes":25},[9,13],{"measure":10,"description":11,"timeFrame":12},"CBCT-Derived Peri-Implant Bone Volume","The peri-implant bone volume will be assessed using cone-beam computed tomography (CBCT) at baseline and 6 months after dental implant placement. Changes in bone volume between baseline and the 6-month follow-up will be evaluated and compared between the test and control groups.","Baseline and 6 months after implant placement",{"measure":14,"description":15,"timeFrame":12},"CBCT-Derived Peri-Implant Radiographic Density","Peri-implant radiographic density will be assessed using cone-beam computed tomography (CBCT) at baseline and 6 months after dental implant placement. Changes in radiographic density between baseline and the 6-month follow-up will be evaluated and compared between the test and control groups.",[17,21],{"measure":18,"description":19,"timeFrame":20},"Implant Stability Quotient (ISQ)","Implant stability will be assessed using resonance frequency analysis and expressed as Implant Stability Quotient (ISQ) values. ISQ will be measured at the time of implant placement and at the 6-month follow-up, and changes will be compared between the test and control groups.","At implant placement and 6 months after implant placement",{"measure":22,"description":23,"timeFrame":24},"Dental Implant Survival Rate at 6 Months","Implant survival will be assessed by determining whether the dental implant remains in situ and clinically functional without removal during the 6-month follow-up period.","Up to 6 months after implant placement",null,{"allocation":27,"interventionModel":28,"interventionModelDescription":29,"primaryPurpose":30,"observationalModel":25,"timePerspective":25,"maskingInfo":31},"RANDOMIZED","PARALLEL","Participants are randomized to either the test group, receiving A-PRF combined with hyaluronic acid during dental implant placement, or the control group, receiving conventional dental implant placement.","TREATMENT",{"masking":32,"maskingDescription":33,"whoMasked":34},"SINGLE","The CBCT outcome assessor will be blinded to participant group allocation. CBCT images will be coded before assessment so that the assessor cannot identify whether participants belong to the test or control group.",[35],"OUTCOMES_ASSESSOR",[37,45],{"label":38,"type":39,"description":40,"interventionNames":41},"Dental Implant + A-PRF and Hyaluronic Acid","EXPERIMENTAL","Participants receive delayed dental implant placement with adjunctive application of advanced platelet-rich fibrin (A-PRF) combined with hyaluronic acid at the implant site.",[42,43,44],"Procedure: Delayed Dental Implant Placement","Procedure: Advanced Platelet-Rich Fibrin (A-PRF)","Device: Hyaluronic Acid 1.5%",{"label":46,"type":47,"description":48,"interventionNames":49},"Dental Implant Alone","ACTIVE_COMPARATOR","Participants receive delayed dental implant placement without adjunctive A-PRF or hyaluronic acid.",[42],[51,56,60],{"type":52,"name":53,"description":54,"armGroupLabels":55,"otherNames":25},"PROCEDURE","Delayed Dental Implant Placement","A dental implant was surgically placed into a healed edentulous site using a standardized delayed-placement protocol. This procedure was performed in both the test and control groups.",[38,46],{"type":52,"name":57,"description":58,"armGroupLabels":59,"otherNames":25},"Advanced Platelet-Rich Fibrin (A-PRF)","Autologous advanced platelet-rich fibrin (A-PRF) was prepared from the participants' venous blood using a standardized centrifugation protocol and applied at the dental implant site. In the test group, A-PRF was used in combination with hyaluronic acid as an adjunct to delayed dental implant placement.",[38],{"type":61,"name":62,"description":63,"armGroupLabels":64,"otherNames":25},"DEVICE","Hyaluronic Acid 1.5%","In the test group, 1.5% hyaluronic acid is combined with autologous advanced platelet-rich fibrin (A-PRF) and applied locally at the dental implant site during delayed dental implant placement. The control group does not receive hyaluronic acid.",[38],[66],{"name":67,"affiliation":5,"role":68},"Samar A salamah, BDS","PRINCIPAL_INVESTIGATOR",[70],{"name":71,"role":72,"phone":73,"phoneExt":25,"email":74},"Samar A Salamah, BDS","CONTACT","+967777277949","samarali777277949@gmail.com",[76],{"facility":77,"status":78,"city":79,"state":80,"zip":25,"country":81,"countryCode":82,"cosmosGeoPoint":83,"geoPoint":88,"contacts":89},"Beauty Smile Dental Center","RECRUITING","Sanaa","Sana'a","Yemen","YE",{"type":84,"coordinates":85},"Point",[86,87],44.20646,15.35452,{"lat":87,"lon":86},[90,91],{"name":71,"role":72,"phone":73,"phoneExt":25,"email":74},{"name":71,"role":72,"phone":25,"phoneExt":25,"email":74},{"type":93,"investigatorFullName":94,"investigatorTitle":95,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"SPONSOR_INVESTIGATOR","Samar Ali Abdu Salamah","Master's Candidate in Oral and Maxillofacial Surgery","100653970","effect-of-advanced-prf-and-hyaluronic-acid-on-dental-implant-healing-100653970",false,"NCT07792720","Effect of Advanced PRF and Hyaluronic Acid on Dental Implant Healing","Clinical Efficacy of A-PRF With Hyaluronic Acid\" in Enhancing Bone Formation in Dental Implantation","Inclusion Criteria:\n\n\\- Adults aged 18-65 years.\n\nPatients requiring delayed dental implant placement in a posterior mandibular edentulous site\n\nSufficient residual alveolar bone height and width to permit conventional implant placement without the need for simultaneous guided bone regeneration (GBR), ridge augmentation, or other bone-grafting procedures.\n\nGood general health or a medically controlled and stable systemic condition compatible with elective implant surgery and not expected to materially compromise wound or bone healing.\n\nNon-smokers with no current use of tobacco products.\n\nAcceptable oral hygiene and a periodontal condition compatible with implant surgery following any required professional treatment and reassessment.\n\nAbility and willingness to undergo the required clinical and radiographic assessments, including CBCT examinations at baseline and at the 6-month follow-up.\n\nAbility and willingness to attend the scheduled follow-up visits and comply with the study procedures.\n\nProvision of written informed consent before study participation.\n\nExclusion Criteria:\n\n\\-\n\nAny uncontrolled systemic disease or medical condition that conensions for conventional implant placement without augmentation.\n\nRequirement for immediate implant placement, simultaneous guided bone regeneration, ridge augmentation, or any other adjunctive bone-grafting procedure.\n\nInability or unwillingness to complete the required 6-month clinical and radiographic follow-up.traindicates elective implant surgery or may substantially impair wound or bone healing, including uncontrolled diabetes mellitus.\n\nImmunocompromised status or current systemic immunosuppressive therapy.\n\nCurrent or previous use of oral or parenteral bisphosphonates or other antiresorptive medications associated with a risk of medication-related osteonecrosis of the jaw.\n\nPregnancy at the time of screening or enrollment.\n\nUnresolved active periodontal disease or active local infection involving the intended implant site, including suppuration.\n\nInadequate oral hygiene that persists after professional oral-hygiene instruction, necessary periodontal treatment, and reassessment.\n\nInsufficient residual alveolar bone dim","ALL","18 Years","65 Years",{"count":107,"type":108},30,"ESTIMATED","INTERVENTIONAL",[111],"NA","This randomized parallel-group clinical trial aimed to evaluate the clinical efficacy of advanced platelet-rich fibrin (A-PRF) combined with hyaluronic acid (HA) in enhancing peri-implant bone formation in patients undergoing delayed dental implant placement. Participants will be allocated to either a test group, in which A-PRF combined with HA is applied at the implant site, or a control group receiving conventional implant placement without adjunctive biomaterials. Peri-implant bone changes will be assessed using cone-beam computed tomography (CBCT), including radiographic bone density and bone volume measurements. Implant stability will also be evaluated using resonance frequency analysis at the time of implant placement and during follow-up. Additional clinical outcomes include postoperative pain and implant survival. The participants will be followed up for six months after implant placement.",[114,115],"Partial Edentulism","Dental Implant Placement",[115,117,118,119,120,121,122,123,124],"Advanced Platelet-Rich Fibrin","A-PRF","Hyaluronic Acid","Osseointegration","Implant Stability","Cone-Beam Computed Tomography","Peri-Implant Bone","Bone Formation","2026-08-29",{"date":127,"type":128},"2026-09-02","ACTUAL",{"date":130,"type":128},"2025-06-05",{"date":132,"type":108},"2027-06",{"name":94,"class":6},1]